Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 393

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 1A
Chunk 393
---
			September 2030 - Oct 2030

			79,651

			79,651

			$
			36.75 - 40.18

			March 2025 - Sep 2031

			56,865

			56,865

			$
			25.97

			March 2025 - Feb 2032

			109,767

			91,887

			$
			4.10 - 10.01

			March 2025 - Oct 2033

			378,039

			360,159

The options exercisable at September 30, 2025 had a weighted average exercise price of $25.59 and an intrinsic value of $0.00 and a weighted average remaining life of 67 months. There were 17,880 options at September 30, 2025 that had not vested with a weighted average exercise price of $6.77 and an intrinsic value of $0.00 and a weighted average remaining life of 91 months.

F-18

EDESA BIOTECH, INC.

Notes to Consolidated Financial Statements

For the Years Ended September 30, 2025 and 2024

The fair value of options granted during the year ended September 30, 2024 was estimated using the Black-Scholes option valuation model using the following assumptions:

			Year Ended September 30, 2024

			Risk free interest rate

			4.92
			%

			Expected life (years)

			5

			Expected share price volatility

			97.26
			%

			Expected dividend yield

			0.00
			%

As of September 30, 2025, the Company had approximately $0.01 million of unrecognized share-based compensation expense, which is expected to be recognized over a period of 12 months.

Restricted share units

The Company's 2019 Plan allows restricted share units (“RSUs”) to be granted to directors, officers, employees and certain external consultants and advisers. Under the 2019 Plan, the RSU term is not to exceed 10 years. The fair value of RSUs is determined based on the market price of the Company’s common shares on the grant date.

The following is a summary of changes in the status of RSUs from October 1, 2024 through September 30, 202